GE's Clarient, Acorn align for molecular oncology testing
Clarient, a GE Healthcare company, and Acorn Research have formed a collaboration around molecular testing of tumor samples.
The agreement will establish a standardized testing protocol across the Acorn network of oncology community practices and hospitals with treatment guidelines and clinical trial opportunities, the companies stated.
The collaboration will establish a system for the collection of an array of tumor-specific biomarker data at the time of the patient’s initial cancer diagnosis. Clarient’s cancer diagnostics portfolio, combined with Acorn’s oncology network and bioinformatics platform, will enable the patient’s medical team to determine a treatment regimen for the patient’s tumor-specific biomarker profile, according to the companies.
The Clarient-Acorn collaboration also could enable matching biomarker data with outcomes data from clinical trials and clinical practice for the identification of new prognostic markers and biomarker-specific treatments.
The agreement will establish a standardized testing protocol across the Acorn network of oncology community practices and hospitals with treatment guidelines and clinical trial opportunities, the companies stated.
The collaboration will establish a system for the collection of an array of tumor-specific biomarker data at the time of the patient’s initial cancer diagnosis. Clarient’s cancer diagnostics portfolio, combined with Acorn’s oncology network and bioinformatics platform, will enable the patient’s medical team to determine a treatment regimen for the patient’s tumor-specific biomarker profile, according to the companies.
The Clarient-Acorn collaboration also could enable matching biomarker data with outcomes data from clinical trials and clinical practice for the identification of new prognostic markers and biomarker-specific treatments.